# *Author Index*
# *Volumes 35 and 36*

**A**
Abdelmawla AH, 36:77
Abe Y, 35:55
Akeson A, 36:155
Antona A, 35:107
Antos M, 36:73
Arce A, 35:69
Arnot MI, 36:29
Attolini L, 35:211

**B**
Baersch G, 36:63
Bagger JP, 36:13
Balsa D, 36:53
Bateson AN, 36:29
Bazan E, 36:81
Belardinelli L, 35:203
Bellanca L, 35:107
Benveniste J, 36:219
Beretz A, 36:69
Beume R, 35:91
Black SC, 35:179
Bohnke R, 36:155
Bradshaw CM, 36:77
Breschi MC, 35:131
Breyssens A, 35:167
Brien JF, 36:97
Bruguerolle B, 35:211
Bucca V, 35:107

**C**
Calderone V, 35:131
Cam MC, 35:111
Capezzone de Joannon A, 36:21
Caprino L, 35:153
Cassel GE, 35:159
Catalin J, 35:211
Chagneau F, 35:139
Clottens FL, 35:167
Constantinou CE, 35:191
Coupar IM, 36:147

**D**
D'Amico C, 35:107
de Certaines JD, 35:139
De Raeve H, 35:167
Debon C, 36:223
Decrinis M, 35:203, 36:205
Demedts M, 35:167
Dever JA, 36:185
Di Pasquale P, 35:107
Dickinson RG, 36:131
Domanovits H, 35:203
Duan J, 35:83
Durham SK, 35:3

**F**
Fernandes BH, 35:83
Ferrando R, 36:53
Forn J, 36:53
Fosbraey P, 35:159
Frøbert O, 36:13
Frölich JC, 36:63
Fukushima S, 35:19

**G**
Gabel RA, 36:189
Gantenbein M, 35:211
García-Rafanell J, 36:53
Gill JM, 36:171
Giral M, 36:53
Goetz A, 36:171
Gregersen H, 36:13
Grossmann V, 36:199
Grzybowski J, 36:73
Guarini S, 35:101

**H**
Haefner D, 35:91
Han SB, 36:33, 36:163
Hariton C, 36:223
Hashimoto M, 35:19, 36:45

Journal of Pharmacological and Toxicological Methods 36, 229–231 (1996)
© 1996 Elsevier Science Inc.
655 Avenue of the Americas, New York, NY 10010

1056-8719/96/$15.00

Hatzelmann A, 35:91
Heifetz CL, 36:185
Hirano H, 36:45
Hirohashi M, 35:25
Hong DH, 36:163
Hope W, 36:137
Hornfeldt BJ, 35:45
Hunder G, 36:211
Hyun BH, 36:33

I
Ichikawa N, 36:45
Igić R, 35:63
Inczeffy Z, 35:145
Irving P, 36:171
Ishida Y, 35:19
Ishisu R, 35:55
Isokawa S, 35:19
Issaevitch T, 35:223
Iwamoto K, 36:45
Izzo AA, 36:219

J
Jaquenod M, 36:123
Jaramillo J, 35:83
Joannides ET, 36:185
Johnson RG, 36:81
Jung GL, 35:83

K
Kang JS, 36:163
Kasper K, 35:203, 36:205
Kastner P, 36:155
Kenakin TP, 36:171
Kim HM, 36:33, 36:163
Kim MS, 36:163
King AR, 36:131
Kitano Y, 35:25
Kivlighn SD, 36:189
Kopecká L, 36:199
Kopecký J, 36:199
Květina J, 36:199

L
Lacarelle B, 35:211
Lacroix P, 35:139
Langley RW, 36:77
Lautt WW, 35:77
Le Rumeur E, 35:139
Le Tallec N, 35:139
Legare DJ, 35:77
Levasseur R, 35:139
Licata G, 35:107
Lindner W, 36:205
Liu L, 36:147
Liu WT, 35:121
Lutz MW, 36:171

M
Madeira VMC, 35:35
Malta TE, 36:185
Mangano G, 36:21
Marks GS, 36:97
Martin IL, 36:29
Martin V, 36:69
Martinotti E, 35:131
Masumura S, 35:19, 36:45
Mather LE, 36:123
McLeod AL, 35:83
McNeill JH, 35:111
Megill JR, 35:3
Merlos M, 36:53
Mikkelsen EO, 36:13
Milanese C, 36:21
Min BK, 36:33
Momose K, 35:11, 35:19
Moran JH, 36:41
Moreno AJM, 35:35
Morgan PH, 36:171
Murakami E, 35:19

N
Nakano T, 35:55
Nakatsu K, 36:97
Nakayama K, 35:19
Naora K, 36:45
Nemery B, 35:167
Nicholls PJ, 35:217
Nomura M, 35:25
Nyborg NCB, 36:13

O
Oh GT, 36:33, 36:163
Onishi K, 35:55
Osborn JW, 35:45

P
Page RL, 35:173
Palazzoadriano M, 35:107
Palmeira CM, 35:35
Pang H, 35:121
Paterna S, 35:107

Pellegrini A, 35:131
Percicot CL, 36:223
Peri G, 36:21
Perillo MA, 35:69
Pierce TL, 36:137

**Q**
Queen K, 36:171

**R**
Rabin RA, 36:81
Ranaei RA, 36:189
Raper C, 36:137
Rapoport RM, 36:81
Raval P, 35:31
Ren Y, 35:121
Riazi-Farzad B, 35:217
Richelson E, 35:11
Rimele T, 36:171
Riviere JE, 35:173
Robinson J, 36:155
Rodger IW, 35:179
Rönnhedh C, 36:123
Rose D, 36:171
Rossi V, 36:21

**S**
Santajuliana D, 35:45
Sarkadi A, 35:145
Sasaki T, 35:19
Scatizzi R, 35:131
Schnell CR, 36:223
Schnellmann RG, 36:41
Schroeder K, 36:155
Schudt C, 35:91
Schumacher WA, 35:3
Schümann K, 36:211
Schwarzl I, 36:205
Sekioka K, 35:55
Seligmann B, 36:155
Semecký V, 36:199
Sesnie JC, 36:185
Severin CM, 36:81
Sewell RD, 35:217
Shapiro MA, 36:185
Spencer PSJ, 35:1
Stark G, 36:205
Stark U, 35:203, 36:205
Steinbacher TE, 35:3
Stella C, 35:153
Sterz F, 35:203
Stětinová V, 36:199
Szabadi E, 36:77

**T**
Takasuna K, 35:25
Tamolang MB, 35:121
Tamura K, 35:19
Tillig B, 35:191
Togna AR, 35:153
Togna G, 35:153
Trafny EA, 36:73
Trejtnar F, 36:199
Tritthart HA, 35:203
Trzeciakowski JP, 36:103

**U**
Ueda Y, 35:55
Usui C, 35:25

**V**
Vaden SL, 35:173
Van Loon GW, 36:97
Villard PH, 35:211
Vukomanovic DV, 36:97

**W**
Wallace KB, 35:35
Wasan KM, 36:1
Wiesel M-L, 36:69
Wong PY, 35:121
Woods JH, 35:223

**X**
Xie H, 35:77

**Y**
Yamada M, 35:11
Yun Y-P, 36:33

**Z**
Zernig G, 35:223
Zhang YL, 35:77
Zhu L, 35:77
Zoutman DE, 36:97

# *Subject Index*
# *Volumes 35 and 36*


**A**

ACE inhibition, comparing different inhibitors of renin-angiotensin system, 35:83
Acetylcholine, aortic multiple-ring preparation for functional studies and, 35:131
Acidic drugs, bile-exteriorized rat as source of acyl glucuronides and, 36:131
Acyl glucuronides, bile-exteriorized rat as source of, 36:131
Adaptation, intestinal transfer in isolated intestinal segments, 36:211
Adenosine nucleotidase, vascular endothelial ADPase activity evaluation and, 35:153
ADP, vascular endothelial ADPase activity evaluation, 35:153
$\alpha_2$-Adrenoceptors, rat ileum effects, 36:147
Alfentanil, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Alpha-chymotrypsin, radio-telemetry system to record intraocular pressure and, 36:223
*p*-Aminohippurate, renal function measurement and, 36:189
Amphotericin B
  lipoprotein composition and, 36:1
  nephrotoxicity, 36:199
Analgesia, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Annamycin, lipoprotein composition and, 36:1
Anti-convulsant activity assessment, electroshock and, 35:25
Antibody responses, SH assay and, 36:33
Antimicrobial agents, in vitro model to test efficacy of , 36:73
Antinociception, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Antithrombotic and thrombolytic activity, reproducible model in rats, 35:101
Aorta
  multiple-ring preparation for functional studies, 35:131
  nitric oxide-sensitive electrode and, 35:19
[$^3$H]Apafant, binding to rabbit platelet membranes, 36:53
Apoptosis
  rapid fluorescence assay for LDH release and, 36:44
  sodium nitroprusside and, 35:11
Arterial pressure, ganglionic blockade protocol to assess neurogenic pressor activity and, 35:45
Arterial thrombosis, aspirin and, 35:3
Aspirin, arterial thrombosis and, 35:3
Atrial flutter, simulated, 35:203
AV node
  rate-dependent effects of verapamil, diltiazem, and digoxin on, 36:205
  simulated atrial flutter and, 35:203

**B**

Benzodiazepine, osmotic minipumps and, 36:29
Bifurcations, stimulus-response analysis and, 36:103
Bile-exteriorized rats, acyl glucuronides source, 36:131
Bioenergetics, mitochondria membrane potential, 35:35
Bladder, videomicroscopic imaging of peristalsis, 35:191
Blood-brain barrier, cerebral microvascular endothelial cells and in vitro drug transport, 36:45
Blood coagulation, aspirin and, 35:3
Blood pressure
  comparing different inhibitors of renin-angiotensin system and, 35:83
  heparin-filled catheter and, 36:69
Bovine aorta, vascular endothelial ADPase activity evaluation and, 35:153
Bovine serum albumin, binding affinity constants of soluble ligand-receptor complex and, 35:69
Bronchoalveolar lavage (BAL), leukocyte differentiation and, 35:91

**C**

Calcium transient, myocardial ischemia and, 35:55
Carbachol
  nitric oxide-sensitive electrode and, 35:19
  rat stomach fundus and, 35:217



Journal of Pharmacological and Toxicological Methods 36, 233–238 (1996)


© 1996 Elsevier Science Inc.


655 Avenue of the Americas, New York, NY 10010

1056-8719/96/$15.00

Carboxyhemoglobin level, tobacco smoke intoxication and, 35:211
Cardiac muscle, mathematical model of isometric contraction of isolated, 36:171
Cardiac relaxation, mathematical model of isometric contraction of isolated cardiac muscle, 36:171
Carotid artery thrombosis, reproducible model in rats, 35:101
Cat, insulin sensitivity test with euglycemic technique, 35:77
Catheterization, blood pressure and heparin-filled catheter, 36:69
Cell death, rapid fluorescence assay for LDH release and, 36:44
Cell-signaling, stimulus-response analysis and, 36:103
Charcoal adsorption, radioimmunoassay optimized for reproducible measurement of rat plasma insulin, 35:111
Charcoal-extracted plasma, radioimmunoassay optimized for reproducible measurement of rat plasma insulin, 35:111
Chlorisondamine, neurogenic pressor activity and, 35:45
Cholinergic nerves, drug effects, 36:147
Chronic drug delivery, osmotic minipumps and, 36:29
Cisplatin, isolated perfused tumor and skin flap model and, 35:173
Collagen dressing, in vitro model to test efficacy of antimicrobial agents, 36:73
Contraction, dimethylformamide effects on in vivo fatigue and metabolism in skeletal muscle, 35:139
Cumulative dose-reponse curves, noradrenaline effects, 36:77
Cyclosporin A, nephrotoxicity, 36:199
Cyclosporin G, chromatographic separation, 35:121
Cyclosporin metabolites, chromatographic separation, 35:121
Cyclosporine, lipoprotein composition and, 36:1
Cynomolgus monkeys, analysis of IL-1 antagonists, 36:155
Cytochrome P450, chromatographic separation of cyclosporin G metabolites and, 35:121
Cytotoxicity
  fixation procedure of leukemia cells in sulforhodamine B cytotoxicity assay, 36:163
  mitochondria membrane potential, 35:35

**D**

Daytime variability, visual-evoked responses and electroencephalographic activity evaluation in rats and, 35:145
Dependence, induction and quantitation of methadone, 36:137
Diazepam, osmotic minipumps and, 36:29
Diclofenac, $PGE_2$ effects on trachea and, 36:63
Digoxin, myocardial ischemia and, 35:55
Dimethylformamide, effects on in vivo fatigue and metabolism, 35:139
Dioxin, antibody production measurement and, 36:33
Dissociation constant, binding affinity constants of soluble ligand-receptor complex, 35:69
Dopamine, soman intoxication and, 35:159
Dorsal hand vein, dose-reponse curves to noradrenaline and, 36:77
Dorsal raphe nucleus, pargyline on 5-HT binding in, 36:81
Dose-reponse curves, noradrenaline effects, 36:77
Drug delivery, osmotic minipumps and chronic, 36:29
Drug-specific binding, rate-dependent effects of verapamil, diltiazem, and digoxin on AV node, 36:205
Dyslipidemia, hydrophobic drugs and, 36:1

**E**

Effective renal plasma flow, determination, 36:189
Efficacy
  calculation of agonist efficacy and apparent in vivo affinity, 35:223
  stimulus-response analysis and, 36:103
[$^3$H]8-OH-DPAT, binding to DRN, 36:81
Electric damage, reproducible model of arterial thrombosis in rats and, 35:101
Electroencephalographic activity, quantitative evaluation in rats, 35:145
Electroshock, seizure test, 35:25
Endothelium
  aortic multiple-ring preparation for functional studies and, 35:131
  rat brain endothelial culture and in vitro drug transfer, 36:45
Endothelium-dependent relaxation, nitric oxide-sensitive electrode and, 35:19
Enteric nerves, drug effects, 36:147
Euglycemic technique, insulin sensitivity test with, 35:77
Ex vivo model, analysis of IL-1 antagonists, 36:155

**F**

Fast Atom Bombardment Mass Spectrometry, chromatographic separation of cyclosporin G metabolites, 35:121
FCS, antibody production measurement and, 36:33
Ferret, arterial thrombosis, 35:3
[$^3$H]5-HT, binding to DRN, 36:81
5-HT, rat stomach fundus and, 35:217
5-$HT_{1A}$ receptor, binding to DRN, 36:81
Flunitrazepam, binding affinity constants of soluble ligand-receptor complex and, 35:69

Fluorescence assay, LDH release, 36:44
FMLP-induced aggregation, 36:21

**G**
GABA, soman intoxication and, 35:159
Glaucoma, radio-telemetry system to record intraocular pressure in, 36:223
Glomerular filtration rate, determination, 36:189
Glucose, insulin sensitivity test with, 35:77
Glycopeptide, antibody production measurement and, 36:33
Guinea pigs
  comparing different inhibitors of renin-angiotensin system, 35:83
  leukocyte differentiation in bronchoalveolar lavage (BAL), 35:91
  mathematical model of isometric contraction of isolated cardiac muscle, 36:171

**H**
Half-life, mRNA, 35:31
Hamsters, ear swelling test and local lymph node assay assessment in, 35:167
Heart, isolated perfused working, 35:63
Heparin-filled catheter, blood pressure and, 36:69
Hepatic enzymate activities, tobacco smoke intoxication and, 35:211
Hexamethonium, neurogenic pressor activity and, 35:45
HI-6, soman intoxication and, 35:159
High performance liquid chromatography (HPLC)
  paf-acether in human blood and, 35:121
  separation of cyclosporin G metabolites, 35:121
Hydrogen peroxide, sodium nitroprusside and, 35:11

**I**
IFN-β, mRNA levels, 35:31
IL-1, analysis of IL-1 antagonists, 36:155
IL-1ra, analysis of IL-1 antagonists and, 36:155
Imaging, videomicroscopic imaging of peristalsis and, 35:191
Impedance planimetry, coronary artery pharmacodynamics and, 36:13
In vitro, intestinal transfer in isolated intestinal segments, 36:211
In vitro model, antimicrobial agents efficacy and, 36:73
In vivo affinity, calculation of agonist efficacy and apparent, 35:223
Increasing-current, electroshock, 35:25
Indomethacin, FMLP-induced aggreagation and, 36:21
Infarct size, experimental myocardial ischemic and reperfusion injury and, 35:179
Inositol, cardiac level determination, 35:107
Inotropy, mathematical model of isometric contraction of isolated cardiac muscle and, 36:171
Insulin sensitivity test, modified euglycemic technique for, 35:77
Intact animals, cardiac inositol level measurement, 35:107
Intestinal absorption, intestinal transfer in isolated intestinal segments, 36:211
Intraocular pressure, radio-telemetry system to record, 36:223
Inulin, renal function and, 36:189
Iothalamate, urineless renal clearance and, 36:123
Ischemia, cardiac inositol level measurement and, 35:107
Ischemic myocardium, experimental reperfusion injury and, 35:179
Isolated heart, working, 35:63
Isolated perfused tumor and skin flap model, cisplatin and, 35:173
Isolated perfusion, cisplatin and, 35:173
Iterative maps, stimulus-response analysis and, 36:103

**K**
Kinetic, rate-dependent effects of verapamil, diltiazem, and digoxin on AV node, 36:205

**L**
Lactate dehydrogenase, fluorescence assay for, 36:44
Left ventricular function, myocardial ischemia and, 35:55
Leukemia cells, fixation procedure in sulforhodamine B cytotoxicity assay, 36:163
Leukocyte differentiation, bronchoalveolar lavage (BAL) and, 35:91
Lipid transfer protein, hydrophobic drugs and, 36:1
Lipopaf, paf-acether in human blood and, 35:121
Lipoproteins, hydrophobic drugs and, 36:1
Local lymph node assay, assessment of ear swelling test and, 35:167
Longitudinal and circular muscle, drug effects, 36:147
Lyapunov exponents, stimulus-response analysis and, 36:103

**M**
Magnetic resonance spectroscopy, dimethylformamide effects on in vivo fatigue and metabolism measured by 31P-, 35:139
Mathematical model, isometric contraction of isolated cardiac muscle, 36:171

Methadone, induction and quantitation of dependence, 36:137
Methods, 5-HT and carbachol in subsections of rat stomach fundus strip, 35:217
Mice
  assessment of local lymph node assay and mouse ear swelling test, 35:167
  electroshock seizure test, 35:25
  intestinal transfer in isolated intestinal segments, 36:211
  novel rapid throughput phototolerance screen in mice, 36:185
  tobacco smoke intoxication effects on carboxyhemoglobin and hepatic enzymate activities in, 35:211
Microplate filtration system, [$^3$H]apafant binding to rabbit platelet membranes, 36:53
Milrinone, myocardial ischemia and, 35:55
Mitochondria, membrane potential, 35:35
Modeling, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Monkeys, analysis of IL-1 antagonists and cynomolgus, 36:155
Monoamine oxidase, binding to DRN, 36:81
Morphine, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Mouse ear swelling test, assessment of local lymph node assay and, 35:167
mRNA, half-life determination, 35:31
Multiple-ring, aortic multiple-ring preparation for functional studies, 35:131
Muscle mechanics, mathematical model of isometric contraction of isolated cardiac muscle, 36:171
Myocardial ischemia, calcium transport and left ventricular function in, 35:55

**N**

Naloxone-precipitated withdrawal, induction and quantitation of methadone dependence and, 36:137
Nephrotoxicity, xenobiotics, 36:199
Neuroblastoma, sodium nitroprusside and, 35:11
Neurogenic pressor activity, ganglionic blockade protocol to assess, 35:45
Neutrophil accumulation, experimental myocardial ischemic and reperfusion injury and, 35:179
Nifedipine, coronary artery pharmacodynamics and, 36:13
Nitric oxide
  -sensitive electrode, 35:19
  sodium nitroprusside and, 35:11
Nitric oxide
  -sensitive electrode, 35:19
Noncumulative dose-reponse curves, noradrenaline effects, 36:77
Nonlinear dynamics, stimulus-response analysis and, 36:103
Nonsteroidal anti-inflammatory drugs (NSAIDs), FMLP-induced aggreagation and, 36:21
Noradrenaline, dose-reponse curves to, 36:77
Norepinephrine, aortic multiple-ring preparation for functional studies and, 35:131
Nystatin, lipoprotein composition and, 36:1

**O**

Ocular hypertension, radio-telemetry system to record intraocular pressure and, 36:223
Oncosis, rapid fluorescence assay for LDH release and, 36:44
Operational model, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Opioids, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Osmotic minipumps, diazepam and, 36:29
Oxazolone, ear swelling test and local lymph node assay assessment, 35:167

**P**

PAF receptor binding, [$^3$H]Apafant and, 36:53
Para-aminohippurate, urineless renal clearance and, 36:123
PCR reactions, IFN-β mRNA, 35:31
PFC assay, antibody production measurement and, 36:33
$PGE_2$, effects on trachea, 36:63
Phosphatidylcholine, paf-acether in human blood and, 35:121
Photically evoked afterdischarge, visual-evoked responses and electroencephalographic activity evaluation in rats and, 35:145
Phototolerance, novel rapid throughput phototolerance screen in mice, 36:185
Phrases, rapid fluorescence assay for LDH release, 36:41
Plasma insulin, radioimmunoassay optimized for reproducible measurement of rat, 35:111
Platelet aggregation, aspirin and, 35:3
Potassium, coronary artery pharmacodynamics and, 36:13
Potassium dichromate, ear swelling test and local lymph node assay assessment, 35:167
Pro-convulsant activity assessment, electroshock and, 35:25
Protein kinase C, measurement in blood vessels, 36:87
*Pseudomonas aeruginosa*
  pyocyanin analysis by adsorptive stripping voltammetry and, 36:73
  in vitro model to test efficacy of antimicrobial agents and, 36:73

**R**
Rabbit platelet membranes, [$^3$H]Apafant binding to, 36:53
Rabbits, radio-telemetry system to record intraocular pressure, 36:223
Radioimmunoassay
  chromatographic separation of cyclosporin G metabolites, 35:121
  reproducible measurement of rat plasma insulin and, 35:111
Rapid filtration, binding affinity constants of soluble ligand-receptor complex and, 35:69
Rapid screening method, novel rapid throughput phototolerance screen in mice, 36:185
Rat ileum, drug effects, 36:147
Rat stomach fundus, 5-HT and carbachol in, 35:217
Rate dependency
  effects of verapamil, diltiazem, and digoxin on atrioventricular conduction, 36:205
  simulated atrial flutter and, 35:203
Rats
  bile-exteriorized rat as source of acyl glucuronides, 36:131
  blood pressure and heparin-filled catheter, 36:69
  cerebral microvascular endothelial cells and in vitro drug transport, 36:45
  drug effects on ileum, 36:147
  insulin sensitivity test with euglycemic technique, 35:77
  intestinal transfer in isolated intestinal segments, 36:211
  isolated working heart model, 35:63
  leukocyte differentiation in bronchoalveolar lavage (BAL), 35:91
  renal function measurement without radioisotopes, 36:189
  reproducible model of arterial thrombosis, 35:101
  soman intoxication, 35:159
  urineless renal clearance, 36:123
  visual-evoked responses and electroencephalographic activity evaluation, 35:145
Reactivity, bile-exteriorized rat as source of acyl glucuronides and, 36:131
Receptor reserve, calculation of agonist efficacy and apparent in vivo affinity, 35:223
Refractoriness, simulated atrial flutter and, 35:203
Renal blood flow, determination, 36:189
Renal cells, rapid fluorescence assay for LDH release and, 36:44
Renal clearance, urineless, 36:123
Renal function, determination, 36:189
Renal hypertension, comparing different inhibitors of renin-angiotensin system and, 35:83
Renal pelvis, videomicroscopic imaging of peristalsis and, 35:191
Renin-angiotensin system, comparing different inhibitors, 35:83
Renin inhibition, comparing different inhibitors of renin-angiotensin system, 35:83
Reperfusion injury, experimental ischemic myocardium and, 35:179
Rifampicin, chromatographic separation of cyclosporin G metabolites and, 35:121

**S**
Seizure threshold, electroshock, 35:25
Serial determination, urineless renal clearance, 36:123
Serotonin receptor, pargyline on 5-HT binding in dorsal raphe nucleus, 36:81
SH assay, antibody production measurement and, 36:33
Skeletal muscle, dimethylformamide effects on in vivo fatigue and metabolism, 35:139
Smooth muscle, protein kinase C translocation, 36:87
Sodium nitroprusside, cellular death via, 35:11
Soluble ligand-receptor complex, binding affinity constants of, 35:69
Solvent, dimethylformamide effects on in vivo fatigue and metabolism, 35:139
Soman, intoxication, 35:159
Spare receptors, calculation of agonist efficacy and apparent in vivo affinity, 35:223
SRB assay, fixation procedure of human leukemia cells, 36:163
*Staphylococcus aureus*, in vitro model to test efficacy of antimicrobial agents and, 36:73
Stasis, reproducible model of arterial thrombosis in rats and, 35:101
Statistics, mathematical model of isometric contraction of isolated cardiac muscle, 36:171
Stimulus amplication, stimulus-response analysis and, 36:103
Sucklings, intestinal transfer in isolated intestinal segments, 36:211
Sulforhodamine B cytotoxicity assay, fixation procedure of human leukemia cells, 36:163

**T**
TCA, fixation procedure of leukemia cells in sulforhodamine B cytotoxicity assay, 36:163
Thin-layer chromatography (TLC), paf-acether in human blood and, 35:121
Threshold phenomenon, stimulus-response analysis and, 36:103
Thromboxane inhibitor, arterial thrombosis and, 35:3
Time constant

rate-dependent effects of verapamil, diltiazem, and digoxin on AV node, 36:205
simulated atrial flutter and, 35:203
Tissue culture, in vitro drug transport and, 36:45
Tobacco smoke intoxication, effects on carboxyhemoglobin and hepatic enzymate activities, 35:211
Trachea, $PGE_2$ effects on, 36:63
Translocation, protein kinase C in smooth muscle, 36:87
Transmural stimulation, rat ileum and, 36:147
Transport, cerebral microvascular endothelial cells and in vitro drug, 36:45
Trimethaphan, neurogenic pressor activity and, 35:45
Triphenyltetrazolium stain, experimental myocardial ischemic and reperfusion injury and, 35:179
Tube preparation, $PGE_2$ effects on trachea and, 36:63

**U**

Ureter, videomicroscopic imaging of peristalsis and, 35:191
Urineless renal clearance, 36:123
Urodynamics, videomicroscopic imaging of peristalsis, 35:191

**V**

Vascular endothelial ADPase, activity evaluation, 35:153
Vascular smooth muscle, nitric oxide-sensitive electrode and, 35:19
Vasoconstriction, coronary artery pharmacodynamics and, 36:13
Ventricular rate, simulated atrial flutter and, 35:203
Videomicrometry, $PGE_2$ effects on trachea and, 36:63
Visual-evoked potential, quantitative evaluation in rats, 35:145
Voltammetric, adsorptive stripping, 36:97

**W**

Working, heart model, 35:63

**Y**

Yohimbine-induced dysrhythmias, isolated working heart model and, 35:63

**Z**

Zomepirac, bile-exteriorized rat as source of acyl glucuronides and, 36:131